Clinical Trials Browser

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Neoplasm Metastasis

Colorectal Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Patient Compliance

Breast Neoplasms

Pancreatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplastic Cells, Circulating

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Pancreatic Neoplasms

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Neuroma, Acoustic, Neurofibromatosis 2

Neoplasm Metastasis

Breast Neoplasms

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

Breast Neoplasms, Breast Neoplasms, Male

HER2 Positive Breast Cancer

Advanced Cancer

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Breast Neoplasms

Pituitary Neoplasms, Prolactinoma

Colorectal Neoplasms

HER2-Positive Early Stage Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Ductal, Breast

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Clinical Trials

PIKHER2

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

MOST plus

M14LTK

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

HELEX

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

DETECT III

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

ROME

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

GW

TEAL

ICK

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Concentration and Activity of Lapatinib in Vestibular Schwannomas

TSAP

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Bevacizumab in Multiple Phase I Combinations

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer

STELA

MetAction

HERACLES

PAMELA

EPHOS-B

KHLAD